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ABSTRACT 
 
The proto-oncogene c-kit plays an important role in the development and survival of mast cells. Gain-of-
function mutations in c-kit are one of the most characteristic events in mast cell leukemia (MCL) but as yet 
there is no clinically approved treatment for the disease. Here we describe growth inhibition of human MCL 
cell lines by the use of RNAi against c-kit or its mutant form. Retroviral transduction of HMC1.1 and 
HMC1.2 cell lines with vectors carrying DNA to be transcribed to RNAi against the wild type or mutant c-kit 
messengers reduced Kit protein levels considerably, decreased cell proliferation, and increased the apoptotic 
levels five  days  after retroviral infection. Thus  RNAi  targeted  against Kit  or  its  mutant  form  could  be 
considered as a new  antiproliferative agent against human mast leukemia cell lines, especially HMC1.2 cells 
which are resistant to the Kit tyrosine kinase inhibitor, imatinib mesylate. 
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INTRODUCTION 
 
The  c-kit  proto-oncogene  codifies  for  a  tyrosine  kinase 
receptor that is essential for the proliferation and survival 
of  hematopoyetic  stem  cells,  melanocytes,  insterstitial 
cells of Cajal, germinal cells and mastocytes. Mutations in 
c-kit have been associated with several diseases, such as 
gastrointestinal  stromal  tumours  (GISTs)  and  mast  cell 
leukemia  (MCL)  (Orfao  et  al,  2007),  a  rare  form  of 
mastocytosis  characterized  by  the  infiltration  of  large 
burdens  of  tissue  mast  cells  into  bone  marrow  and 
peripherical  blood.  Allele-specific  gain-of-function 
mutations  either  at  the  juxtamembrane  or  the  catalytic 
domain of c-kit have been found in MCL (Longley et al, 
2001).  Imatinib  mesylate,  the  clinically  approved  c-Kit 
tyrosine kinase inhibitor, is able to block the survival of 
cells from the human leukemia mast cell line HMC1.1 as 
well as some cases of both MCL and GISTs, all of them 
harbouring mutations in the juxtamembrane domain of the 
protein (Hartmann  et al, 2005). The drug nevertheless has 
no  effect  on  the  survival  of  MCL  cells  harbouring 
mutations  at  the  catalytic  domain  of  c-Kit,  such  as  the 
human leukemia MCL line HMC1.2 (Akin et al, 2003). 
Additionally,  tumours  harbouring  c-kit  mutations  that 
respond  to  imatinib  mesylate,  may  develop  new  point 
mutations that confer them resistance to the drug (Haller et 
al, 2007; Nakagomi and Hirota, 2007). 
 
 RNAi has the potential for treatment of disorders where 
dominant gene mutations contribute to the progression of 
the disease (Kim and Rossi, 2007). In this report, we have 
investigated the effect of using shRNA to silence Kit in 
both  the  imatinib-sensitive  HMC1.1  and  the  imatinib-
resistant HMC1.2 cell lines. We found that RNAi may be 
used as an alternative treatment for MCL. 
 
MATERIALS AND METHODS 
 
Cell culture 
HMC 1.1 and HMC1.2 cell lines were a generous gift from 
Drs  Luis  Escribano  (Hospital  Virgen  del  Valle,  Toledo, 
Spain)  and  David  Butterfield  (Mayo  Clinic,  Rochester,  
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USA),  respectively.  Cells  were  grown  in  Iscove’s 
Modified Dulbecco’s medium (IMDM) supplemented with 
10% (v/v) foetal bovine serum and 100µg/ml penicillin. 
The Phoenix amphotropic cell line was cultured in DMEM 
supplemented with 10% (v/v) foetal bovine serum. 
 
Antibodies and reagents 
Rabbit  polyclonal  anti-Kit  (sc-168)  was  obtained  from 
Santa  Cruz Biotechnology, Inc.  Rabbit polyclonal anti-
actin  secondary  antibody  was  obtained  from  Sigma- 
Aldrich, Inc. STI-571 (Imatinib mesylate) was a gift from 
Novartis; working stocks were prepared by dissolving it in 
PBS at 1 mM and stored at -20ºC. 
 
Retroviral-based Kit knockdown by shRNAs  
We  followed  several  previously  described  methods 
(Brummelkamp et al, 2002) to generate interfering RNAs 
against wild type and mutant (Val560Gly, Asp816Val) c-
kit  messengers, present in HMC1.1 and HMC1.2 cells. 
Short-hairpin  DNA  sequences  selected  from  GenBank 
accession  number  NM_00222  were  synthesised  and 
cloned  between  the  BglII  and  XhoI  restriction 
endonuclease  sites  of  the  pSUPERretro  vector  that 
carries the puromycin resistance pac gene. Five shRNA-
encoding retroviral vectors were tested in HMC1.1 and 
HMC1.2 cells. 
 
Retroviral infection of human leukemia mast cells  
Plasmid-retroviral vectors carrying pac gene (as selectable 
marker)  and  one  of  the  cloned  DNAs  encoding  Tot 
shRNAs, Mut shRNAs, non-allele specific shRNAs were 
transfected  into  Phoenix  amphotrophic  packaging  cell 
lines using lipofectamine and Plus Reagent according to 
the manufecturer’s instructions. Empty vector was used as 
non-shRNA  expressing  control.  Forty-eight  hours  after 
transfection, viral supernatants were colleted and used to 
infect HMC1.1 and HMC1.2 cell lines in the presence of 
polybrene (8 µg/ml). Cells were incubated overnight and 
then  allowed  to  recover  for  24  hr  in  fresh  medium. 
Twenty-four  hours  after  retroviral  infection,  puromycin 
was added to cell cultures. 
 
Quantitative RT-PCR   
Five  days  after  infection  of  HMC1.1  cells  by  empty 
retroviral  vector  (control)  or  by  one  of  the  shRNA-
expressing vectors (Mut 1, Mut 2, Mut 3) total RNA was 
isolated  using  the  RNAeasy  Extraction  Kit  (Qiagen, 
Germany)  according  to  the  manufacturer’s  instructions. 
cDNA  was synthesized using avian  myeloblastosis
 virus 
reverse  transcriptase  (Promega,  Madison,  WI),  followed 
by single PCR reactions using the appropriate primer pairs 
for the amplification of either c-kit wild type or mutant 
alleles. Quantitative PCR assays were performed with the 
ABI  Prism  7700  Sequence  Detection  System  (Applied 
Biosystems) using Sybergreen. As PCR controls, we used 
RNA  isolated  from  NCI-H510  human  lung  cancer  cells 
(which  carry  wild-type  c-kit)  (Carney  et  al,  1985)  and 
human  RNA  from  HMC1.2  cells  (which  carry  c-kit 
Val560Gly/Asp816Val  mutant).  The  amplified  products 
were isolated and cloned into pGEM-T vector. The PCR 
cycling  conditions  were:  35  cycles  at  95ºC  for  30  sec, 
60ºC  for  30  sec  and  72ºC  for  30  sec.  The  following 
primers were used in PCR amplification: 
Forward primer for the wild type allele: 
5’ CATGTATGAAGTACAGTGGAAGGTT CT 
 
Forward primer for the Val560Gly mutant allele: 
5’-ATGTATGAAGTACAGT GAAGGTTCG 
 
Reverse primer for both wild type and mutant alleles: 
5’-GGAAGTTGTGTTG  GGTCTATGTAAAC 
 
 Western blot analysis 
Cells were harvested in TNSEV lysis buffer (50mM Tris-
HCl pH7.5; 2  mM EDTA; 2mM sodium orthovanadate, 
1%, v/v, NP-40) supplemented with 1 mM PMSF, 1 µg/ml 
leupeptin and 1 µg/ml aprotinin, and incubated on ice for 
15 min. The homogenate was centrifuged for 15 min at 
14000  rpm  and  the  supernatant  was  taken  for  protein 
quantification. Protein samples (70 µg) were denatured in 
Laemmli buffer at 95ºC, and separated in 8% (v/v) and 
10%  (v/v)  SDS-PAGE  gel  at  100  V  for  2  hr,  and 
electrophoretically transferred onto nylon membranes. The 
membranes were incubated for 1 hr with the appropriate 
primary antibodies dissolved in 5% (w/v) powdered non-
fatty milk and 1% (v/v) Tween-20 in PBS. After washing, 
membranes  were  incubated  for  45  min  with  the 
correspondent secondary antibodies. The bound antibodies 
were detected by chemiluminiscence using ECL reagents. 
  
Flow cytometric apoptosis assay 
The percentage of cell death was determined according to 
the  supplier’s  instructions  (BD,  Pharmingen).  After 
retroviral  infection,  HMC1.1  and  HMC1.2  cells  were 
washed in PBS and resuspended in 100 µl of annexin/7-
AAD  binding  buffer  and  incubated  for  15  min  at  room 
temperature in dark. Thereafter, 400µl of binding buffer 
was added to each sample and analyzed by flow cytometry 
using  a  FACS  Calibur  cytometer  (BD,  Heinderg, 
Germany). 
 
Cell viability assays  
These  were  based  on  trypan  blue  exclusion  or  3,4-(4,5-
dimethylthiazol-2-yl)-2.5-diphenyl-tetrazolium  bromide 
(MTT) assay. For the former, infected cells were washed 
in PBS, and resuspended in 1 vol of PBS and an equal 
volume of trypan blue. After 1 min incubation viable cells, 
represented as white spots, were counted using a Neubauer 
chamber  under  a  light  microscope.  For  the  MTT  assay, 
3,4-(4,5-dimethylthiazol-2-yl)-2.5-diphenyl-tetrazolium 
bromide (MTT) was dissolved in PBS at 1 µg/µl. Viable 
cells converted the MTT to a blue formazan precipitate. 
After  2  hr  incubation  at  37ºC  in  the  dark,  dark-blue 
formazan  was  solubilised  with  2ml  of  DMSO  and  the 
absorbance at 540nm was measured. 
 
Statistical analysis 
Values  are  expressed  as  mean  ±  SD;  comparisons  were 
made using Student’s t-test. 
 
RESULTS 
 
Knockdown of wild type and mutant Kit proteins by 
allele-specific shRNAs 
We  designed  five  different  shRNAs  targeting  different 
regions  of  c-kit  messengers.  As  shown  in  Figure  1A,  
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HMC1.1  cells  had  an  allele-specific  point  mutation  at 
position-1680  of  c-kit  cDNA,  which  corresponds  to  a 
Val560Gly  substitution,  and  HMC1.2  cells  had  two 
different  allele-specific  point  mutations,  one  at  position 
1680 and the other one at position 2448 of the same allele 
of c-kit, which corresponds to a Val560Gly and Asp816val 
substitution as described previously in the literature (Akin 
C et al, 2003). Two shRNAs targeted c-kit mRNA outside 
the  mutated  region  inhibiting  the  expression  of  both 
mutant and wild type mRNAs (Total 1 and Total 2). Other 
two  shRNAs  were  directed  against  the  V560G  mutant 
messenger of c-kit present in both HMC1.1 and HMC1.2 
cells (RNAi Mut 1, RNAi Mut 2), and finally there was 
one  non-specific  allelic  RNAi  (RNAi  Mut  3).  Both 
HMC1.1 and HMC1.2 cell lines were infected with either 
the  empty  control  retrovirus  or  the  retroviral-based 
shRNAs.  Five  days  after  retroviral  infection  and 
puromycin  selection  of  HMC1.1  and  HMC1.2  cells,  we 
tested  the  efficiency  of  retroviral-based  shRNAs  on  Kit 
protein levels (Figure 1B). Total 2 RNAi against both wild 
type and mutant messengers of the gene, gave rise to 86% 
knockdown in HMC1.1 and  95% protein knockdown in 
HMC1.2,  respectively.  The  Mut  1  RNAi  against  the 
mutant  messenger  V560G  inhibited  50  and  58%  of  the 
total protein levels in HMC1.1 and HMC1.2, respectively 
and  the  Mut  2  RNAi  did  so  for  52%  and  57%  of  Kit 
protein.    The  non-allele  specific  RNAi  (Mut  3  RNAi) 
inhibited Kit protein levels not only in HMC1.2 cells but 
also in HMC1.1 cells. The empty retroviral vector control 
did not show any significant reduction of Kit protein. 
 
 
A: 
 
 
 
 
 
B: 
 
 
Figure 1. Localization of c-kit point mutations. (A) Identification 
of allele-specific c-kit point mutations in HMC1.1 and HMC1.2 
cell lines after amplification by RT-PCR and sequencing. The 
G/T polymorphism for Val560Gly mutation and the A/T 
polymorphism for Asp816Val mutation in c-kit are underlined. 
(B) Western blot analysis showing the amount of Kit protein 
after transduction of HMC1.1(upper panel) and HMC1.2 (lower 
panel) cells with retroviruses carrying an empty retrovirus 
(Control vector) and with retroviruses expressing shRNA 
against: both messenger RNAs of c-kit (Tot1, Tot2); the mutated 
messenger RNAs (Mut1, Mut 2), or a non-allele specific shRNA 
(Mut 3).  Actin was used as protein loading control.  
 
 
 
Quantification of c-kit mutant transcripts after RNAi 
expression in HMC1.1 cells 
Next, we performed a quantitative RT-PCR to confirm the 
efficacy and specificity of the RNAi directed against the 
mRNA of the mutant allele of c-kit. We designed specific 
primers that amplified only the mutant or the wild type c-
kit  cDNA  (Figure  2A).  The  confirmation  of  the  strict 
allelic discrimination of these primers was examined in a 
test  experiment  primed  with  either  wild  type  or  mutant 
cDNAs. As shown in Figure 2B wild type but not mutant 
c-kit cDNA was amplified in the presence of the wild type 
primers, while conversely mutant but not wild type cDNA 
was  amplified  in  the  presence  of  the  mutant  primers. 
Figure 2B also shows the amplification of both wild type 
and  mutant  c-kit  cDNAs  in  retrotranscribed  mRNA 
prepared from HMC1.1 and HMC1.2 cells, with both wild 
type and mutant primers. 
 
Some but not all of the shRNAs differentially suppressed 
the  wild  type  and  mutant  c-kit  mRNAs.  The  results 
obtained were normalised with respect to those obtained 
with cells infected with an empty retrovirus. The levels of 
c-kit mutant mRNA in HMC1.1 cells treated with the Mut 
1  and  Mut  2  RNAi  were  reduced  relative  to  wild  type 
mRNA  by  93%  and  79%,  respectively,  indicating  the 
specificity of these two shRNAs for the mutant messenger 
of c-kit (Figure 2C). Nevertheless, when cells were treated 
with Mut 3 RNAi, the ratio of mutant to wild type c-kit 
mRNAs was similar to that observed in cells infected with 
the  control  empty  retrovirus,  in  agreement  with  our 
previous results in  which Mut 3 RNAi inhibited  mutant 
and wild type mRNAs in HMC1.1 cells indiscriminately. 
 
Effects of Kit knockdown in HMC1.1 and HMC1.2 cells 
Knowing  that  Kit  is  important  for  the  proliferation  and 
survival of mast cells, we tested whether RNAi mediated 
c-kit knockdown reduced mast cell survival. We used in 
most  of  the  experiments  retrovirus  transcribing  Mut  1 
RNAi, which was the most efficient in the reduction of the 
mutant mRNAs of c-kit, and in some others Tot 2 RNAi, 
which reduced both forms of Kit indiscriminately. Twelve 
days after retroviral infection and puromycin selection, the 
proliferation of mast cells was markedly reduced by both 
retroviruses. Both total Kit knockdown (Tot) and mutant 
Kit  knockdown  (Mut)  effectively  reduced  HMC1.1  and 
HMC1.2 cell viability (Figure 3A and B, respectively). To 
evaluate  whether  the  decrease  in  cell  viability  was 
associated  to  apoptosis,  we  measured  the  percentage  of 
annexin-V positive cells 5 days after infection. The death 
following  infection  in  the  two  cell  lines  represented 
27.97%  for  HMC1.1  and  16.05%  for  HMC1.2, 
respectively as compared to cells infected with the control  
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empty  retrovirus  (Figure  3C).  We  also  found  that  the 
inhibition of only mutant c-kit mRNA showed even higher 
levels of apoptosis, being 44.64% and 27.63% in HMC1.1 
and HMC1.2 cells, respectively. 
 
 
 
 
 
Figure 2. Selective knockdown of c-kit mutant messengers in 
HMC1.1 cells. (A) Sequence details of c-kit wild type and mutant 
cDNAs. (B) Agarose gel detection of amplified wild type or 
mutated c-kit cDNAs by standard PCR, using the wild type 
primers for the upper part of the figure and the mutant primers 
for the lower part: lane a, DNA amplified from cloned wild type 
c-kit originally from NCI-H510 lung cancer cells; lane b, DNA 
amplified from cloned mutant c-kit originally from HMC1.2 
cells; lane c, product of  RT-PCR amplification of RNA from 
HMC1.1 cells; d: product of RT-PCR amplification of RNA from 
HMC1.2 cells. (C) Estimated ratio of mutant to wild type 
mRNAs by qRT-PCR using sybergreen in HMC1.1 cells after 
treatment with control empty retrovirus, and retroviruses 
transcribing Mut 1 RNAi, Mut 2 RNAi and Mut 3 RNAi. 
 
 
A: 
 
 
B: 
 
 
C: 
 
 
 
Figure 3. Cell survival of human mast leukemia cells after Kit 
knockdown. (A) Survival assay of HMC1.1 cells after gene 
silencing of all c-kit mRNAs (Tot) or only the mutant mRNA 
(Mut) at different times after retroviral infection. (B) Survival 
assay of HMC1.2 cells as in A. (C) Percentage of HMC1.1 (grey) 
and HMC1.2 (black) apoptotic cell death 5 days after Kit 
knockdown (annexin-V positive cells).  
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Imatinib  mesylate  resistant  HMC1.1  cell  line  is 
sensitive to shRNA-mediated c-kit gene silencing  
Imatinib  mesylate  is a potent tyrosine  kinase inhibitor of 
Kit, PDGFR, and the fusion protein ABL-BCR (Kovalenko 
et al, 1994; Druker et al, 1996; Heinrich et al, 2000). We 
treated  both  HMC1.1  and  HMC1.2  MCL  cell  lines  with 
imatinib mesylate and compared the results with the ones 
obtained by shRNA-mediated c-kit gene silencing (Figure 
4), showing as expected, that the drug drastically reduced 
cell  viability  in  HMC1.1,  but  not  in  HMC1.2  cells  as 
previously described,
 (Akin et al, 2003). On the other hand, 
Tot and Mut sh-RNAs silencing c-kit reduced considerably 
the viability of both HMC1.1 and HMC1.2 cells. 
 
 
 
 
 
Figure 4. HMC1.2 cell line is resistant to imatinib mesylate but 
sensitive to Kit knockdown. The viability of HMC1.1 and 
HMC1.2 cells is shown 5 days after the various treatments shown 
at the bottom of the graph that are: empty vector (Control 
vector), imatinib mesylate, RNAi against total c-kit mRNAs 
(Tot) and RNAi against the mutant allele of c-kit mRNA (Mut). 
 
 
 
DISCUSSION 
 
Kit is up-regulated in several malignant diseases such as 
myeloproliferative  disorders  (Beghini  et  al,  2002), 
gastrointestinal stromal tumours (Hornick et al, 2007) and 
neuroblastomas (Vitali et al, 2003) although  its  role in the 
progression of the different types of cancer is not clearly 
established (Sattler and Salgia, 2004). 
 
We  have  knockdown  Kit  protein  in  both  HMC1.1  and 
HMC1.2 cell lines with RNAi. The ability of the RNAi to 
discriminate between the mutant and wild type messengers 
of  c-kit  has  also  been  shown.    Similar  discriminatory 
inhibition has been demonstrated for other genes such as 
p53, k-ras and SOD-1, whose mutations are related to the 
progression of  Li-Fraumeni syndrome, pancreatic cancer 
and amyotrophic lateral sclerosis respectively (Martinez et 
al, 2002; Duursma and Agami, 2003; Raoul et al, 2005). 
The expression of RNAi specific for the mutant form of c-
kit resulted in a reduction of the corresponding mRNA in 
HMC1.1 cells of up to 93%, and also to a greater decrease 
in  cell  viability  than  when  both  mutant  and  wild  type 
forms of the mRNA were inhibited. These results confirm 
the  possibility  of  using  allele  discrimination  to  alleviate 
illness caused by negative dominant mutations.  
Both cell lines HMC1.1 and HMC1.2 were responsive to 
the  anti-proliferative  effects  of  either  total  c-kit  RNAi  or 
mutant  c-kit  RNAi  in  a  time-dependent  manner.  The 
observed  apoptotic  cell  death  is  probably  a  result  of  the 
down-regulation of Bcl-2 and consequent reduction in the 
activation of downstream effectors such as Akt, Stat3 and 
Erk1/2, which are necessary for the normal development of 
mast cells as previously described (Ning et al, 2001; Nishida 
et  al,  2002;  Wandzioch  et  al,  2004).  Mast  leukemia 
HMC1.1 and HMC1.2 cell lines are good models to study 
the susceptibility of mutant c-kit variants to tyrosine kinase 
inhibitors such as imatinib mesylate. The HMC1.2 cell line, 
as shown here and previously (Akin et al, 2003), is resistant 
to imatinib mesylate as a consequence of a point mutation at 
D816V, the catalytic domain of the protein, while HMC1.1 
harbouring  exclusively  the  V560G  point  mutation  is 
sensitive to the drug.  The highly specific effect of RNAi in 
reducing c-kit  mRNA could  be used  for the treatment of 
other cancers resistant to imatinib mesylate, such as GISTs 
which,  although  they  respond  to  this  drug  at  first,  often 
develop  new  mutations  that  confer  them  resistance.  We 
have demonstrated here that the exclusive inhibition of the 
mutant allele of c-kit is more efficient than the inhibition of 
both mutant and wild type alleles and this could be a good 
strategy  for  decreasing  cancer  cell  survival.  The  system 
could also be used in combination with other therapies for 
the treatment of c-kit related malignancies. 
 
CONCLUSIONS 
 
• RNAi-mediate  inhibition  is  efficient  in  discriminating 
between mutant and wild type alleles from c-kit oncogene, 
thus have therapeutic potential; such as in the case of mast 
cell  leukaemia,  caused  by  dominant,  gain-of-function 
mutations. 
 
• RNAi-mediated  degradation  of  mutant  c-kit  triggers  a 
decrease in cell proliferation and induces apoptosis. 
 
• Cell death is induced in both sensitive to imatinib mesylate 
(HMC1.1) or resistant (HMC1.2) cell lines. 
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